acridines has been researched along with Myotonic Dystrophy in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chikuni, T; Hazemi, ME; Katahira, M; Kobayashi, T; Nagatsugi, F; Onizuka, K; Sasaki, K; Sato, N; Usami, A; Yamaoki, Y | 1 |
Lee, J; Nguyen, L; Wong, CH; Zimmerman, SC | 1 |
Baranger, AM; Fu, Y; Ramisetty, SR; Wong, CH; Zimmerman, SC | 1 |
3 other study(ies) available for acridines and Myotonic Dystrophy
Article | Year |
---|---|
Selective alkylation of T-T mismatched DNA using vinyldiaminotriazine-acridine conjugate.
Topics: Acridines; Alkylation; Base Pair Mismatch; Base Pairing; Base Sequence; DNA; DNA Replication; DNA-Directed DNA Polymerase; DNA-Directed RNA Polymerases; Humans; Molecular Targeted Therapy; Myotonic Dystrophy; Thymidine; Transcription, Genetic; Triazines; Trinucleotide Repeats; Vinyl Compounds | 2018 |
Small molecules that target the toxic RNA in myotonic dystrophy type 2.
Topics: Acridines; Cell Survival; HeLa Cells; Humans; Imidazoles; Inhibitory Concentration 50; Intercalating Agents; Kinetics; Ligands; Microsatellite Repeats; Microscopy, Confocal; Myotonic Dystrophy; Pyrimidines; RNA; RNA-Binding Proteins | 2014 |
Selective inhibition of MBNL1-CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2).
Topics: Acridines; Base Sequence; DNA; Humans; Intercalating Agents; Ligands; Myotonic Disorders; Myotonic Dystrophy; Pyrimidines; Repetitive Sequences, Nucleic Acid; RNA; RNA-Binding Proteins | 2011 |